医疗研发外包成分股数据 申万3级
851563.SI (27)
数据更新时间：2024-05-31
"-"表示无或者负数
| 序号 | 股票代码 | 股票简称 | 纳入时间 | 申万1级 | 申万2级 | 申万3级 | 价格
|
市盈率
|
市盈率ttm
|
市净率
|
股息率
|
市值（亿元）
|
归母净利润同比增长(03-31)
|
归母净利润同比增长(12-31)
|
营业收入同比增长(03-31)
|
营业收入同比增长(12-31)
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603456.SH | 九洲药业 | 2023-07-06 | — | — | 医疗研发外包 | 15.09 | 13.14 | 13.72 | 1.57 | 2.64% | 135.73 | -15.65% | 12.17% | -15.73% | 1.44% |
| 2 | 300363.SZ | 博腾股份 | 2014-02-12 | — | — | 医疗研发外包 | 14.75 | 30.18 | — | 1.49 | 3.28% | 80.54 | -131.20% | -86.69% | -50.81% | -47.87% |
| 3 | 301520.SZ | 万邦医药 | 2023-10-10 | — | — | 医疗研发外包 | 45.2 | 27.88 | 26.72 | 2.02 | — | 30.13 | 18.81% | 9.48% | 25.14% | 31.07% |
| 4 | 600721.SH | 百花医药 | 2008-01-25 | — | — | 医疗研发外包 | 5.83 | 171.6 | 82.6 | 3.05 | — | 22.26 | 209.02% | 137.31% | 20.03% | 5.54% |
| 5 | 300149.SZ | 睿智医药 | 2010-12-29 | — | — | 医疗研发外包 | 4.86 | — | — | 1.69 | — | 24.29 | 10.87% | -339.83% | -12.68% | -14.19% |
| 6 | 688238.SH | 和元生物 | 2023-09-25 | — | — | 医疗研发外包 | 5.65 | — | — | 1.81 | — | 36.58 | -32.85% | -425.90% | 93.48% | -29.69% |
| 7 | 301096.SZ | 百诚医药 | 2021-12-27 | — | — | 医疗研发外包 | 61.87 | 24.78 | 23.5 | 2.46 | — | 67.39 | 42.06% | 40.07% | 34.04% | 67.51% |
| 8 | 301201.SZ | 诚达药业 | 2022-01-27 | — | — | 医疗研发外包 | 19.98 | 33.98 | 34.35 | 1.38 | 0.94% | 30.91 | -5.09% | -14.56% | -1.28% | 0.69% |
| 9 | 301333.SZ | 诺思格 | 2022-08-09 | — | — | 医疗研发外包 | 44.49 | 26.28 | 27.24 | 2.41 | 0.35% | 42.71 | -19.95% | 43.27% | 10.19% | 13.15% |
| 10 | 301509.SZ | 金凯生科 | 2023-08-10 | — | — | 医疗研发外包 | 37.05 | 25.71 | 29.82 | 2.1 | 1.54% | 44.63 | -58.83% | 7.51% | -41.87% | 7.00% |
| 11 | 300347.SZ | 泰格医药 | 2012-08-24 | — | — | 医疗研发外包 | 53.93 | 23.04 | 27.58 | 2.3 | 1.03% | 466.47 | -58.65% | 0.91% | -8.00% | 4.21% |
| 12 | 688202.SH | 美迪西 | 2023-09-25 | — | — | 医疗研发外包 | 32.96 | — | — | 1.81 | — | 44.39 | -136.98% | -109.82% | -42.51% | -17.68% |
| 13 | 688265.SH | 南模生物 | 2023-09-25 | — | — | 医疗研发外包 | 25.6 | — | — | 1.17 | — | 19.96 | 9.38% | -281.18% | -5.01% | 20.99% |
| 14 | 002821.SZ | 凯莱英 | 2016-11-25 | — | — | 医疗研发外包 | 76.69 | 12.49 | 14.75 | 1.61 | 2.34% | 283.35 | -55.27% | -31.28% | -37.76% | -23.70% |
| 15 | 688131.SH | 皓元医药 | 2023-09-25 | — | — | 医疗研发外包 | 30.1 | 35.52 | 46.2 | 1.78 | — | 45.27 | -63.76% | -34.18% | 20.68% | 38.44% |
| 16 | 688076.SH | 诺泰生物 | 2023-09-25 | — | — | 医疗研发外包 | 56.89 | 74.43 | 58.24 | 5.75 | — | 121.28 | 215.65% | 26.20% | 71.02% | 58.69% |
| 17 | 300759.SZ | 康龙化成 | 2019-02-11 | — | — | 医疗研发外包 | 20.64 | 23.04 | 24.87 | 2.94 | 0.97% | 368.92 | -33.80% | 16.48% | -1.95% | 12.39% |
| 18 | 688046.SH | 药康生物 | 2023-09-25 | — | — | 医疗研发外包 | 11.65 | 30.06 | 30.36 | 2.24 | — | 47.77 | -5.06% | -3.49% | 11.96% | 20.45% |
| 19 | 300404.SZ | 博济医药 | 2015-05-04 | — | — | 医疗研发外包 | 7.68 | 120.6 | 100.82 | 3.07 | 0.26% | 29.35 | 40.67% | -12.04% | 62.08% | 31.19% |
| 20 | 688621.SH | 阳光诺和 | 2023-09-25 | — | — | 医疗研发外包 | 49.51 | 30.01 | 26.46 | 5.47 | — | 55.45 | 51.77% | 18.08% | 8.53% | 37.76% |
| 21 | 300725.SZ | 药石科技 | 2017-11-17 | — | — | 医疗研发外包 | 31.33 | 31.7 | 33.08 | 2.28 | 0.32% | 62.55 | -14.32% | -37.19% | -1.56% | 8.18% |
| 22 | 301257.SZ | 普蕊斯 | 2022-05-24 | — | — | 医疗研发外包 | 42.76 | 19.41 | 19.79 | 2.36 | 0.41% | 26.15 | -10.22% | 86.06% | 17.42% | 29.65% |
| 23 | 688073.SH | 毕得医药 | 2023-09-25 | — | — | 医疗研发外包 | 33.09 | 27.45 | 30.46 | 1.47 | — | 30.07 | -29.39% | -24.94% | 4.05% | 30.94% |
| 24 | 301230.SZ | 泓博医药 | 2022-11-08 | — | — | 医疗研发外包 | 32.87 | 94.04 | 136.0 | 3.21 | 1.09% | 35.38 | -75.99% | -44.00% | 7.69% | 2.26% |
| 25 | 603127.SH | 昭衍新药 | 2017-09-01 | — | — | 医疗研发外包 | 15.23 | 28.77 | — | 1.43 | 1.88% | 114.21 | -244.98% | -63.04% | -12.07% | 4.78% |
| 26 | 603259.SH | 药明康德 | 2018-05-15 | — | — | 医疗研发外包 | 42.11 | 12.76 | 13.07 | 2.24 | 2.15% | 1226.21 | -10.42% | 9.00% | -10.95% | 2.51% |
| 27 | 688222.SH | 成都先导 | 2023-09-25 | — | — | 医疗研发外包 | 12.64 | 124.38 | 79.07 | 3.69 | — | 50.65 | 248.40% | 61.16% | 54.35% | 12.64% |
免责声明：数据相关栏目所收集数据，均来自第三方个人或企业公开数据以及国家统计网站公开发布数据，数据由计算机技术自动收集更新再由作者校验，作者将尽力校验，但不能保证数据的完全准确。 阅读本栏目的用户必须明白，图表所示结果或标示仅供学习参考使用，均不构成交易依据。任何据此进行交易等行为，而引致的任何损害后果，本站概不负责。
关注微信公众号
获取更多数据
获取更多数据
关闭 X